Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

Core Viewpoint - Neuronetics, Inc. is set to release its fourth quarter 2024 financial and operational results on March 4, 2025, prior to market opening, followed by a conference call to discuss the results [1] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology [3] - The company is a leader in neuroscience, offering the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for mental health conditions [3] - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults with Major Depressive Disorder (MDD) who have not responded to previous antidepressant treatments [3] - The therapy is also FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [3] - Over 6.9 million NeuroStar treatments have been delivered, establishing it as the leading Transcranial Magnetic Stimulation (TMS) treatment for MDD in adults [3] Investor Relations - Investor inquiries can be directed to Mike Vallie or Mark Klausner at ICR Healthcare [4] - Media inquiries can be directed to EvolveMKD [4]